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With the introduction of the newer broad spectrum antibiotics, the systemic
use of sulfonamides has largely been abandoned by dermatologists in the man-
agement of cutaneous diseases. But, as Sulzberger and Baer (1) reviewed in the
Yearbook of 1953—54, there was one singular exception to this trend. Sulfa-
pyridine held a unique, though not absolute, specificity for the control of derma-
titis herpetiformis. The exact mode of action of sulfapyridine is unknown. It
may be through its effect on some unknown microorganism or through some
obscure mechanism on the disease itself (such as, action on cellular respiratory
system (2)). The drug also has a beneficial effect on acrodermatitis continua
(Hallopean), dermatitis repens (1), cystic acne vulgaris (3) and on various types
of eczematous dermatoses (4).
In 1940 an attempt was made by Svartz to formulate an improved sulf on-
amide for the specific treatment of rheumatic polyarthritis and ulcerative
colitis (5). A combination of salicylic acid and sulfapyridine known as salicyl-
azosulfapyridine was compounded. This substance is 4-(Pyridyl-2-Amidosulf-
onyl)-3-carboxyl-4-hydroxyazobenzene xvith the following structural formula:
COOH— /NOHON=NOSO2NH\>
It contains 60 % sulfapyridine and is only partly decomposed to sulfapyridine
and aminosalicylic acid in the body. This accounts for relatively low sulfapyri-
dine blood levels (1 to 2 mg. %) when therapeutic doses are administered (5 to
6 gm. per day) (6) (compare with usual blood concentration of 4 to 6 mg. % ob-
tained with 6 gm. daily dose of old sulfapyridine) (7). Only small amounts of
unchanged and acetylated drug are excreted in the urine. This significantly
lowers the risk of precipitation with normal diuresis. Alkalinization is not
generally performed and no kidney complications have been observed (8). This
drug has an affinity for connective tissue which may or may not have any
therapeutic importance (9). Serious side reactions, such as depression of blood
cells, are very rare. There were no such incidences in 800 cases treated at the
Karolinska Institute in Stockholm (8). This may be due to the low blood con-
centration of sulfonamide which develops. Lehr (10) found that the incidence
of reactions to sulfonamides was proportional to the dosage; the lower the
amounts given, the fewer incidences of reaction. A toxic fever and dermatitis
medicamentosa does occasionally occur but these apparently clear quickly with
withdrawal of the drug.
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It has been extensively used by Bargen (9, 11) at the Mayo Clinic for treat-
ment of severe ulcerative colitis. It is considered one of the drugs of choice.
Because of the experiences with sulfapyridine in treatment of different types
of cutaneous diseases and because of the low toxicity and possible selective
action of salicylazosulfapyridine (e.g. its affinity for connective tissue), a group
of various dermatoses was treated in an effort to evaluate this new drug.
DOSAGE AND METHOD OF ADMINISTRATION
Selected groups of dermatoses which are known to respond to some extent to
sulfapyridine were treated with salicylazosulfapyridine.* The drug was given
as one to two tablets four times daily (2.0 to 4.0 gms. per day). Attempt was
made to maintain a minimum fluid intake of 2000 cc. daily; however, alkaliniza-
tion was not mandatory. This therapy was maintained for one to 16 weeks
depending on the individual responses. Concomitant therapy consisted of bland
symptomatic topical medicaments in most of the dermatoses and a sulfur lotior
for the acne cases.
RESULTS
The responses of 68 cases of various dermatoses are summarized in Table 1.
The pustular element of 28 cases of acne vulgaris was improved in somewhat
more than one-half the series (16 cases); and of these 4 cleared completely.
Twelve showed no significant change after a minimum period of two weeks and
of those that improved, one-third recurred 2 to 4 weeks after withdrawal of
the drug.
Thirty cases of riummular eczema, pustular psoriasis, dyshidrotic eczema of
hands, cellulitis secondary to dermatophytosis and stasis dermatitis and furuncu-
losis responded moderately to excellently to the salicylazosulfapyridine. Seven
cases were entirely refractory.
The response of two severe cases of seborrheic dermatitis was poor.
One case of severe generalized miliaria cleared almost completely in one week
while the patient was on a dose of 4.0 gm. per day.
One case of pyoderma gangrenosum of the legs improved only partially in
eight weeks treatment with the drug. The accompanying ulcerative colitis was
not controlled then, but did respond later to cortisone therapy. This patient was
able to tolerate only 2.0 gms. of salicylazosulfapyridine daily because of nausea
with larger doses.
Of five cases of dermatitis herpetiformis, one had complete morbidistic effect
from as little as 0.5 gm. daily; two had partial control on 1.0 to 4.0 gms. daily
(but was controlled by 1.0 to 2.0 gms. of old, uncoated sulfapyridine) and one
case was completely intolerant to the drug (nausea).
Three cases in the whole series were intolerant to the drug enough to require
discontinuing it. One was from nausea, one from diarrhea, and one from general-
ized eczematous dermatitis medicamentosa which cleared promptly with with-
drawal of the medication.
*The clinical supply of salicylazosulfapyridine (Azulfidine) was furnished through the
courtesy of Mr. L. A. Elwinger of the Pharmacia Labs. Inc.
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TABLE I
Results of various dermatoses treated with salicylazosulfapyridine
Disease Number Daily Dose
(weeks)
I Improve- Intolerant
Pustular
Psoriasis 4 2.0—4.0 3—12 1 2 1
Pyoderma garigre-
vlosum with
ulcerative
colitis 1 2.0 8 1
Nummular
eczema 12 2.0—4.0 2—8 4 7 1
Dermatitis
herpetiformis. . 5 0.5—4.0 1—28 1 2 1 1 (nausea)
Pustular acne 28 2.0—4.0 1—12 4 12 12
Dyshidrotic
eczema of
hands 7 2.0-4.0 2—6 1 3 3
Miliaria, severe. . . 1 2.0 2 1
Seborrheac 2 2.0—4.0 1—2 1 1 (diarrhea)
Furunculosis 2 2.0 1—2 1 1
Cellulitis second-
ary to derma-
tophytosis 5 4.0 2—3 2 3
Cellulitis second-
ary to stasis
dermatitis . . . . 1 2.0 1 1 (dermati-
tis medic-
amen-
tosa)
Total 68
SUMMARY AND CONCLUSIONS
Salicylazosulfapyridine has had a beneficial effect in over half of a series of
sixty-eight cases of various dermatoses. This effect may have been achieved by
liberated free sulfapyridine or by a specific action. Its advantage over sulfapyri-
dine appears to be its lesser toxicity and over the broad spectrum antibiotics,
its lesser cost. It does not seem to be superior to sulfapyridine for cases of derma-
titis herpetiformis. Some of the failures were thought to be due to the lower
dosage of the drug (2.0 gms. per day). In general it is thought that a superior
response was achieved consistently with a larger dose (4.0 gms. per day).
There is no question that salicylazosulfapyridine is a definite adjunct in the
control of the pustular phase of acne vulgaris and of several other dermatoses
which have an infectious element. It does not, however, seem to influence the
underlying pathologic defect.
It should be remembered that although salicylazosulfapyridine has a low
toxicity, it is still a sulfonamide, a derivative of sulfapyridine, which has a
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definite potential for producing toxic reactions. If the dose is high or is to be
maintained for long, then periodic blood counts and urinalysis would be essential.
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